Indication
for the treatment of adult patients with relapsed or refractory (r/r) diffuse large B‑cell lymphoma (DLBCL) after two or more lines of systemic therapy

Medicine details

Medicine name:
tisagenlecleucel (Kymriah)
SMC ID:
SMC2141
Pharmaceutical company
Novartis Pharmaceuticals UK Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full submission
Status
Advice due date:
Q1 2019
SMC meeting date:
Q1 2019
Patient group submission deadline:
03 December 2018